Browse by Journal Title

2024

CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
Eitler, J., Rackwitz, W., Wotschel, N., Gudipati, V., Murali Shankar, N., Sidorenkova, A., Huppa, J.B., Ortiz-Montero, P., Opitz, C., Künzel, S.R., Michen, S., Temme, A., Loureiro, L.R., Feldmann, A., Bachmann, M., Boissel, L., Klingemann, H., Wels, W.S. and Tonn, T.
Journal for ImmunoTherapy of Cancer 12 (2): e008155. 27 February 2024

2023

Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al.
Immisch, L., Papafotiou, G., Popp, O., Mertins, P., Blankenstein, T. and Willimsky, G.
Journal for ImmunoTherapy of Cancer 11 (3): e006784. 14 March 2023

Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa, N., Poncette, L. and Blankenstein, T.
Journal for ImmunoTherapy of Cancer 11 (2): e006001. February 2023

2022

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
Brauneck, F., Fischer, B., Witt, M., Muschhammer, J., Oelrich, J., da Costa Avelar, P.H., Tsoka, S., Bullinger, L., Seubert, E., Smit, D.J., Bokemeyer, C., Ackermann, C., Wellbrock, J., Haag, F. and Fiedler, W.
Journal for ImmunoTherapy of Cancer 10 (12): e004794. 22 December 2022

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma.
Immisch, L., Papafotiou, G., Popp, O., Mertins, P., Blankenstein, T. and Willimsky, G.
Journal for ImmunoTherapy of Cancer 10 (10): e005535. 27 October 2022

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., Blumenberg, V., Hoster, E., Bullinger, L., Locke, F.L., von Bergwelt-Baildon, M., Mackensen, A., Bethge, W., Barba, P., Jain, M.D. and Subklewe, M.
Journal for ImmunoTherapy of Cancer 10 (5): e004475. 17 May 2022

Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Guedan, S., Luu, M., Ammar, D., Barbao, P., Bonini, C., Bousso, P., Buchholz, C.J., Casucci, M., De Angelis, B., Donnadieu, E., Espie, D., Greco, B., Groen, R., Huppa, J.B., Kantari-Mimoun, C., Laugel, B., Mantock, M., Markman, J.L., Morris, E., Quintarelli, C., Rade, M., Reiche, K., Rodriguez-Garcia, A., Rodriguez-Madoz, J.R., Ruggiero, E., Themeli, M., Hudecek, M. and Marchiq, I.
Journal for ImmunoTherapy of Cancer 10 (5): e003487. May 2022

2021

Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta, S., Short, S.A.P., Sise, M.E., Prosek, J.M., Madhavan, S.M., Soler, M.J., Ostermann, M., Herrmann, S.M., Abudayyeh, A., Anand, S., Glezerman, I., Motwani, S.S., Murakami, N., Wanchoo, R., Ortiz-Melo, D.I., Rashidi, A., Sprangers, B., Aggarwal, V., Malik, A.B., Loew, S., Carlos, C.A., Chang, W.T., Beckerman, P., Mithani, Z., Shah, C.V., Renaghan, A.D., Seigneux, S.D., Campedel, L., Kitchlu, A., Shin, D.S., Rangarajan, S., Deshpande, P., Coppock, G., Eijgelsheim, M., Seethapathy, H., Lee, M.D., Strohbehn, I.A., Owen, D.H., Husain, M., Garcia-Carro, C., Bermejo, S., Lumlertgul, N., Seylanova, N., Flanders, L., Isik, B., Mamlouk, O., Lin, J.S., Garcia, P., Kaghazchi, A., Khanin, Y., Kansal, S.K., Wauters, E., Chandra, S., Schmidt-Ott, K.M., Hsu, R.K., Tio, M.C., Sarvode Mothi, S., Singh, H., Schrag, D., Jhaveri, K.D., Reynolds, K.L., Cortazar, F.B. and Leaf, D.E.
Journal for ImmunoTherapy of Cancer 9 (10): e003467. October 2021

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.
Çınar, Ö., Brzezicha, B., Grunert, C., Kloetzel, P.M., Beier, C., Peuker, C.A., Keller, U., Pezzutto, A. and Busse, A.
Journal for ImmunoTherapy of Cancer 9 (7): e002410. 30 July 2021